Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CLB-001
- Development stage
- Preclinical
- Lead developer
- Yale University
- Modality
- RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
CLB-001 is an engineered transfer RNA (tRNA) therapeutic containing 5-fluorouracil (5-FU) developed by Cloverleaf Bio. It is designed as a competitive substrate-mimic inhibitor that targets and irreversibly inhibits multiple tRNA-modifying enzymes, which cancer cells are abnormally dependent on to sustain high-throughput translation of oncogenic proteins. In preclinical studies, CLB-001 has demonstrated nanomolar potency and high selectivity for cancer cells over healthy cells, outperforming standard of care therapies in models of hepatocellular carcinoma (HCC) and lung adenocarcinoma without showing signs of systemic toxicity.
02
Targets
DUS2 (Dihydrouridine synthase 2)
Beyond the preview
Go deeper on CLB-001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CLB-001.